The Wall Street Journal: Gene-editing firm Intellia announces IPO, deal with Regeneron 0 12.04.2016 02:14 MarketWatch.com Intellia Therapeutics Inc., a biotechnology company working on “editing” defective genes, has disclosed its plans for an initial public offering. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
